welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
The Johns Hopkins Guide for Patients and Families: Familial Adenomatous PolyposisINTRODUCTION This booklet is written fo...
-
Mucosectomy with Handsewn Anastomosis Reduces the Risk of Adenoma Formation in the Anorectal Segment After Restorati...OBJECTIVE : The study compared the risk ...
-
Medstar Franklin Square Medical CenterMedstar Franklin Square Medical Center's...
-
Cleveland ClinicCleveland Clinic is the largest private ...
-
kirsten doumaPostdoc at Academic Medical Center...
-
Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europ...Cancer Prevention Pharmaceuticals, Inc. ...
-
Eicosapentaenoic Acid Reduces Rectal Polyp Number and Size in Familial Adenomatous PolyposisOBJECTIVE : The omega-3 polyunsaturated ...